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Abstract
Background: Metformin is used in the treatment of Diabetes Mellitus type II and improves liver function in patients with
non-alcoholic fatty liver disease (NAFLD). Metformin activates AMP-activated protein kinase (AMPK), the cellular energy
sensor that is sensitive to changes in the AMP/ATP-ratio. AMPK is an inhibitor of mammalian target of rapamycin (mTOR).
Both AMPK and mTOR are able to modulate cell death.
Aim: To evaluate the effects of metformin on hepatocyte cell death.
Methods: Apoptotic cell death was induced in primary rat hepatocytes using either the bile acid glycochenodeoxycholic
acid (GCDCA) or TNFa in combination with actinomycin D (actD). AMPK, mTOR and phosphoinositide-3 kinase (PI3K)/Akt
were inhibited using pharmacological inhibitors. Apoptosis and necrosis were quantified by caspase activation, acridine
orange staining and Sytox green staining respectively.
Results: Metformin dose-dependently reduces GCDCA-induced apoptosis, even when added 2 hours after GCDCA, without
increasing necrotic cell death. Metformin does not protect against TNFa/ActD-induced apoptosis. The protective effect of
metformin is dependent on an intact PI3-kinase/Akt pathway, but does not require AMPK/mTOR-signaling. Metformin does
not inhibit NF-kB activation.
Conclusion: Metformin protects against bile acid-induced apoptosis and could be considered in the treatment of chronic
liver diseases accompanied by inflammation.
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Introduction
Metformin is a drug primarily used in the treatment of Diabetes
Mellitus type II where it suppresses glucose production by the
liver. Recently, metformin was shown to have beneficial effects in
patients with (non-alcoholic) fatty liver diseases (NAFLD) and
poly-cystic ovarian syndrome (PCOS) [1,2]. In patients and
in vivo models of non-alcoholic steatohepatitis (NASH), metfor-
min reduced leptin secretion and aminotransferase levels and
decreased liver size. Moreover, metformin treatment improved
hepatocyte viability in fatty livers [3–8]. In addition, metformin
protected hepatocytes from cell death induced by saturated fatty
acids [9].
Metformin is known to stimulate AMP-activated protein kinase
(AMPK) activity both in whole liver, primary hepatocytes, and a
hepatoma cell line [10–12]. Among the 5 members of the AMPK
family are AMPK-a1 and -a2 that are activated by metformin
[10,13]. AMPK consists of a catalytic a subunit and two regulatory
subunits (b, c; [10,14]. AMPK is involved in insulin signaling,
energy homeostasis, and becomes activated upon a rise in cellular
AMP concentration or changes in the AMP/ATP-ratio. Further-
more, AMPK can be activated by stimuli that do not affect the
AMP/ATP-ratio, like hyperosmotic stress, hypoxia, oxidative
stress or pharmacological compounds [12,14–20]. AMPK activity
is dependent on the phosphorylation of Thr172 in the a subunit
[21].
Activation of AMPK using the cell permeable adenosine
analogue 5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside
(AICAR) was shown to be pro-apoptotic, via activation of JNK
and caspase-3 in liver cells [22]. Also, in a rat hepatoma cell
line AMPK activity stimulated apoptosis, and in pancreatic b-
cells both metformin and AICAR induced apoptosis. In
contrast, AMPK activation reduced apoptosis in astrocytes and
endothelial cells [23]. Moreover, in DLD-1 cells, Ark5, another
AMPK family member, was protective against Fas-mediated cell
death. Ark5 directly inhibited one of the effector caspases,
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caspase-6, and Ark5 activity was shown to be controlled by Akt,
a key regulator in survival signaling [11,15,24–27]. In whole
liver, AMPK activity represses signaling via mammalian target
of rapamycin (mTOR), a downstream target of Akt and
phosphoinositide-3 kinase (PI3K). mTOR is a key player in
transcription, translation, cytoskeletal arrangement, and protein
degradation [14,16,26,28–33]. Akt was found to suppress
apoptosis in various cell types, including liver cells. In a rat
hepatoma cell line, constitutive activation of PI3K blocks
GCDCA-induced apoptosis. In primary rat hepatocytes, the
protection of tauroursodeoxycholic acid (TUDCA) against
GCDCA-induced apoptosis was abolished when the PI3K/Akt
survival pathway was inhibited [34–39]. Several important
survival pathways next to PI3K/Akt are present in hepatocytes,
like the transcription factor nuclear factor-kB (NF-kB) and the
mitogen activated protein (MAP) kinases [40]. Activation of NF-
kB leads to the induction of survival genes and subsequently
inhibition of apoptosis. In cholestatic livers, NF-kB is activated,
and reduces liver injury [41], and glycochenodeoxycholic acid
(GCDCA)-induced apoptosis was reduced by NF-kB activation
in primary rat hepatocytes in vitro [42]. Furthermore, inhibition
of both the PI3K pathway and one of the MAP-kinases p38 or
ERK enhanced bile acid induced cell death in rat hepatocytes
[43].
Considering the controversy about the role of metformin and its
downstream target AMPK in apoptosis and the apparent
beneficial effect of the drug in the treatment of NAFLD, we
investigated the effect of metformin in two different models of
hepatocyte damage. We studied an in vitro model of acute liver
damage triggered by cytokines and a model of chronic liver disease
induced by bile acids. We investigated whether metformin has
effects on hepatocyte survival pathways and whether downstream
targets of metformin modulate hepatocyte cell death. We describe
a hepatoprotective action of metformin against bile acid-induced
apoptosis that is independent of AMPK activation, but dependent
on an intact PI3K/Akt signaling pathway.
Materials and Methods
Animals
Specified pathogen-free male Wistar rats (200–250 g) were
purchased from Charles River Laboratories Inc (Wilmington, MA,
USA). Rats were housed under standard laboratory conditions
with free access to standard laboratory chow and water. Prior to
isolation, rats were fasted overnight, and anesthetized using a
combination of medetomidine/ketamine (i.p. injection). Experi-
ments were approved by the Institutional Animal Care and Use
Committee of the University of Groningen (IACUC-RuG) and
were performed following their guidelines.
Rat Hepatocyte Isolation
Hepatocytes were isolated from rats by a two step collagenase
perfusion as described before [44]. Cell viability was greater than
85% as determined by Trypan Blue exclusion. After isolation,
112,500 cells per cm2 were plated on VitrogenH (Cohesion
Technologies Inc., Palo Alto, CA, USA) coated plates in William’s
E medium (Invitrogen, Breda, The Netherlands) supplemented
with 50 mg/mL gentamycin (Invitrogen) and penicillin-streptomy-
cin-fungizone (Lonza, Verviers, Belgium). During the attachment
period (4 hrs) 50 nmol/L dexamethasone (Dept. of Pharmacy,
UMCG, Groningen, The Netherlands) and 5% fetal calf serum
(Invitrogen) were added to the medium. Cells were cultured in a
humidified incubator at 37uC and 5% CO2.
Experimental Design
Experiments were started 4 hrs after isolation of hepatocytes.
Monolayer cultures were exposed to 50 mmol/L GCDCA
(Calbiochem, La Jolla, CA, USA) for 4 hrs or the indicated time
period, or for 16 hrs to 20 ng/ml recombinant murine tumor
necrosis factor a (mTNFa, R&D Systems, Abingdon, United
Kingdom) in combination with actinomycin-D (ActD, Roche
Diagnostics, Almere, The Netherlands, 200 ng/ml) or a cytokine
mixture consisting of 20 ng/ml mTNFa, 10 ng/ml recombinant
human interleukin-1b (hIL-1b, R&D Systems), 10 ng/ml recom-
binant rat interferon-c (rIFNc, R&D Systems.) and 10 mg/ml LPS
(Escherichia coli, serotype 0127:B8, Sigma-Aldrich, St. Louis, MO,
USA). Bile acid uptake was studied using the fluorescein labeled
bile acid cholyl-lysyl-fluorescein (CLF, BD Biosciences, Breda, The
Netherlands) 2 mmol/L for 1 hr. 1,1-dimethylbiguanide hydro-
chloride (metformin, Sigma-Aldrich) was used at a concentration
range from 0.1–2 mmol/L. Signal transduction pathways were
specifically blocked using 0.1 mmol/L of the AMPK inhibitor 59-
iodotubercidin (Calbiochem), 0.5 mmol/L of the mTOR inhibitor
rapamycin (Calbiochem) or 50 mmol/L of the PI3K inhibitor LY
294002 (Calbiochem). All inhibitors were added 30 minutes prior
to bile acids or cytokines. Each experimental condition was
performed in triplicate wells. Each experiment was performed at
least three times, using hepatocytes from different isolations.
Cells were harvested at the indicated time points after the
addition of the apoptotic stimuli, and washed three times with ice
cold phosphate buffered saline (PBS) before the addition of
hypotonic cell lysis buffer (protein analysis, caspase-3 assay), 2-
times concentrated sample buffer (Western blot analysis) or Tri-
reagent (RNA isolation, Sigma-Aldrich) as described previously
[43].
Caspase Enzyme Activity Assays
Caspase-3 like activity was assayed as described previously [43].
The arbitrary fluorescence unit (AFU) was corrected for the
amount of protein in the cell lysate. Caspase-6 like activity was
assayed according to the manufacturer’s instructions (Biovision,
Mountain View, CA, USA).
Sytox Green and Acridine Orange Nuclear Staining
To determine necrotic cell death at the indicated time points,
hepatocytes were incubated for 15 minutes with Sytox green
(Invitrogen) nucleic acid stain. Sytox green can only enter cells
with compromised plasma membranes, and cannot cross the
membranes of viable cells or apoptotic bodies. Hepatocytes
exposed to 5 mmol/L H2O2 (Merck Chemicals Ltd, Nottingham,
Table 1. Sequences of primers and probes used for
quantitative PCR analysis.
Rat 18S Sense 59-CGG CTA CCA CAT CCA AGG A-39
Antisense 59-CCA ATT ACA GGG CCT CGA AA-39
Probe 59FAM-CGC GCA AAT TAC CCA CTC CCG A-
TAMRA39
Rat iNOS Sense 59-GTG CTA ATG CGG AAG GTC ATG-39
Antisense 59-CGA CTT TCC TGT CTC AGT AGC AAA-39
Probe 59FAM-CCC GCG TCA GAG CCA CAG TCC T-
TAMRA39
doi:10.1371/journal.pone.0071773.t001
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UK) for 6 hrs served as positive control for necrosis. Apoptotic
nuclei were visualized with acridine orange (Sigma-Aldrich) as
described previously [44]. Fluorescent nuclei were visualized using
an Olympus CKX41 microscope at 450–490 nm. Necrosis and
apoptosis were quantified by counting fluorescent nuclei (necrotic
or apoptotic cells) and the total number of cells in 3 randomly
chosen high power fields.
Western Blot Analysis
Western blot analysis of cell lysates was performed by SDS-
PAGE followed by semi dry-blotting to transfer the proteins to
Hybond ECL nitrocellulose membrane (Amersham Biosciences,
Piscataway, NJ, USA). Ponceau S 0.1% w/v (Sigma-Aldrich)
staining was used to ensure electrophoretic transfer. Activation of
AMPK was detected using the polyclonal antibody against
phosphorylated AMPKa (Thr 172, Invitrogen) at a dilution of
1:500. Hepatocytes exposed to 250 mmol/L AICAR (Biomol
Research Laboratories Inc, Plymouth Meeting, PA, USA) for 60
minutes served as positive control for phosphorylation and
activation of AMPK. Akt activation was detected using the
polyclonal antibody against phosphorylated Akt (Ser473, Cell
Signaling Technology, Danvers, MA, USA) at a dilution of
1:1000. After Western blot analysis, blots were stripped as
described previously [44] and incubated with a monoclonal
antibody against b-actin (Sigma-Aldrich, dilution 1:10000) or
GAPDH (Calbiochem, dilution 1:50000).
The blots were analyzed in a ChemiDoc XRS system (Bio-Rad,
Hercules, CA, USA). Protein band intensities were quantified by
Quantity One software (Bio-Rad).
RNA Isolation and Quantitative PCR
RNA isolation was performed as described previously [45].
RNA concentration was determined with the Ribogreen RNA
quantitation reagent and kit (Invitrogen). Reverse transcription
PCR (RT-PCR) was carried out on 2.5 mg of total RNA using
random primers in a total volume of 50 mL using Moloney murine
leukemia virus (M-MLV) reverse transcriptase system (Sigma-
Aldrich) according to the manufacturer’s instruction.
Quantitative PCR was performed on 4 mL 20-times diluted
complementary DNA in a final volume of 20 mL [45]. Fluores-
cence was measured using the ABI PRISM 7700 Sequence
Detector version 1.7 software (Applied Biosystems, Nieuwerkerk
a/d IJssel, The Netherlands) starting with 10 minutes at 95uC,
followed by 40 cycles of 15 seconds at 95uC and 1 minute at 60uC.
Details of primers and probes are listed in Table 1. Each sample
was analyzed in duplicate. 18S mRNA levels were used as
endogenous control.
Statistical Analysis
All numerical results are reported as the mean of at least 3
independent experiments 6 standard error of the mean. For each
experiment, the results were analyzed using the Kruskal-Wallis test
to verify the significance. If P,0.05 for the Kruskal-Wallis test, a
Mann-Whitney U test was used to determine the significance of
differences between experimental groups. A P-value smaller than
0.05 was considered to be statistically significant.
Figure 1. Metformin dose-dependently reduces bile acid-induced caspase-3 activity, but not TNFa/ActD-induced apoptosis. Primary
rat hepatocytes were exposed to metformin (0.1–2 mmol/L) added 10 minutes prior to (A) GCDCA (50 mmol/L, 4 hrs) or (B) TNFa/ActD (20 ng/ml,
200 ng/ml, 16 hrs). Caspase-3 like activity is shown as fold induction compared to control values; control values were set at one. (C) Metformin
prevents GCDCA (4 hrs) induced nuclear condensation as demonstrated by acridine orange staining, but has no effect on TNFa/ActD (16 hrs) induced
nuclear condensation. Percentages represent condensed nuclei. Magnification 20X. (D) Metformin also reduces GCDCA-induced caspase-6 activity.
Caspase-6 like activity was measured in primary rat hepatocytes exposed to GCDCA (50 mmol/L, 4 hrs) and/or metformin (1 mmol/L) and is shown as
fold induction compared to control values; control values were set at one. N= 4 for each experiment. Statistical analysis: * p,0.05 or & p,0.01
compared to control. # p,0.05 compared to GCDCA-treated cells.
doi:10.1371/journal.pone.0071773.g001
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Results
Metformin Dose-dependently Reduces Bile Acid Induced
Apoptosis
To examine a potential hepatoprotective effect of metformin,
two different models for apoptosis were used: bile acid (GCDCA)-
induced apoptosis and TNFa/ActD-induced apoptosis. GCDCA-
induced caspase-3 activity peaks at 4 hrs [43], while for TNFa/
ActD-induced apoptosis, caspase-3 activity is maximal between
12–16 hrs (data not shown). Therefore, these time points were
chosen to study the beneficial effect of metformin. Metformin
inhibited GCDCA-induced caspase-3 activity dose-dependently
from 24% inhibition at 0.1 mmol/L to an almost complete block
(84% inhibition) at a concentration of 2 mmol/L (Fig. 1A). In
contrast, 1 mmol/L metformin, a concentration that blocks
GCDCA-induced caspase-3 activity for 63%, had no effect on
TNFa/ActD-induced caspase-3 activity (Fig. 1B). Metformin (0.1–
2 mmol/L) alone did not induce caspase-3 activity. However,
higher concentrations (5 mmol/L and higher) were toxic to
hepatocytes (data not shown). Acridine orange staining confirmed
the results obtained with the caspase-3 assay. Condensed nuclei
are visible in 47% of GCDCA-treated hepatocytes (Fig. 1C),
whereas in combination with metformin this number of apoptotic
cells is reduced by half to 23%. However, the TNFa/ActD-
Figure 2. Metformin does not delay bile acid-induced apoptosis. Primary rat hepatocytes were exposed to GCDCA (50 mmol/L) without or in
combination with metformin for 4, 6, 9 and 24 hrs. Metformin (1 mmol/L) was added 10 minutes before GCDCA. Control cells are rat hepatocytes not
treated with GCDCA or metformin. At the indicated time points, cells were analyzed for (A) caspase-3 like activity, or (B) nuclear condensation as
indicated by acridine orange staining and expressed as % condensed nuclei. Magnification 20X. N= 4 for each experiment. Statistical analysis: &
p,0.01 compared to control. # p,0.05 compared to GCDCA-treated cells at the corresponding time-point.
doi:10.1371/journal.pone.0071773.g002
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induced nuclear condensation is hardly affected by metformin
(Fig. 1C). Apoptotic cells were not observed in control or
metformin-exposed hepatocytes (Fig. 1C).
Next, the effects of metformin on GCDCA-induced caspase-6
activity were studied. Metformin (1 mmol/L) decreased GCDCA-
induced caspase-6 activity by 46% (Fig. 1D).
To demonstrate that metformin inhibits and not delays bile acid
induced apoptosis, a time course study was performed. At the
indicated time points, from four to nine hrs after addition of
GCDCA, metformin significantly inhibited GCDCA-induced
caspase-3 activity (Fig. 2A). After 24 hrs, the caspase-3 activity
levels of GCDCA and GCDCA plus metformin treated cells were
both comparable to control. Acridine orange staining was
performed to ensure that the peak of caspase-3 activity of
hepatocytes treated with GCDCA plus metformin was not
between any of the time points analyzed. Both 4 and 24 hr after
exposure, GCDCA-induced nuclear condensation was reduced by
metformin by 72% (Fig. 2B).
Metformin does not Block the Uptake of GCDCA at the
Cell Membrane
Next, we examined whether metformin only protects cells when
added prior to GCDCA, or also after bile acid exposure.
Metformin was added either 10 minutes before, simultaneously
with, or 1, 2 or 3 hrs after addition of the bile acid. Metformin
significantly decreased GCDCA induced caspase-3 activity when
added up to 2 hrs after GCDCA (Fig. 3A). No difference in
reduction of caspase-3 activity between a pre-incubation of 10
minutes with metformin or addition at the same time as GCDCA
was detected (data not shown). Furthermore, equal uptake of
fluorescent bile acids in hepatocytes treated with or without
metformin was observed (Figure 3B). These results indicate that
the protective effect of metformin is not due to reduced uptake of
GCDCA into the cell.
Metformin Reduces Apoptosis without Increasing
Necrotic Cell Death
Subsequently, we studied whether the reduction in apoptotic
cell death by metformin results in a shift towards necrotic cell
Figure 3. Metformin protects primary hepatocytes against apoptosis when added after GCDCA, but not by inhibiting bile acid
uptake. Rat hepatocytes were treated without (control) or with GCDCA (50 mmol/L) for 4 hrs (A). GCDCA-treated hepatocytes were co-incubated
with metformin (1 mmol/L) for 1–4 hrs. A longer incubation time with metformin is visualized in the graph by a color change from dark grey to white.
Caspase-3 like activity was measured and is shown as fold induction compared to control values; control values were set at one. N = 4. Statistical
analysis:& p,0.01 compared to control. # p,0.05 compared to GCDCA-treated cells. The protective effect of metformin is not caused by reduced
uptake of GCDCA (B). Primary rat hepatocytes were exposed to the fluorescent bile acid CLF (2 mmol/L) for 1 hr. Metformin (1 mmol/L) was added 10
minutes prior to CLF. Uptake of CLF by hepatocytes was visualized by fluorescent microscopy. N = 3. Representative images 1 hr after incubation are
shown. White arrow: CLF uptake in the bile canaliculi. Upper panel: phase contrast. Lower panel: fluorescence. Magnification 20X.
doi:10.1371/journal.pone.0071773.g003
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death. At the peak of caspase-3 activity, the percentage of necrotic
cells was determined. GCDCA caused necrosis in 11% of the cells,
whereas 7% of the hepatocytes exposed to GCDCA and
metformin were necrotic (Fig. 4). Also after 16 hours exposure,
no significant differences between cultures treated with GCDCA
or GCDCA plus metformin (1 mmol/L) could be observed (Fig. 4).
No significant necrosis was observed in control cultures or cultures
exposed to metformin alone (Fig. 4).
The Anti-apoptotic Effects of Metformin are Dependent
on PI3K/Akt Signaling, but not on AMPK/mTOR Signal
Transduction
The involvement of the known downstream targets of metfor-
min, the AMPK/mTOR pathway was examined. AMPK was
blocked using a pharmacological inhibitor (59-iodotubercidin), and
mTOR activation was prevented by the specific inhibitor
rapamycin. As shown in figure 5A and E, blocking either AMPK
or mTOR had no effect on the anti-apoptotic actions of
metformin and both inhibitors did not change GCDCA-induced
caspase-3 activity or nuclear condensation. Hepatocytes treated
with the inhibitors alone or in combination with metformin
showed caspase-3 values similar to control cells (data not shown).
Interestingly, Western blot analysis demonstrated that hepatocytes
treated for 1 hr with either GCDCA or metformin caused a slight
induction (2-fold) of phosphorylated AMPKa compared to control
cells (Fig. 5B). Cells exposed to both GCDCA and metformin
showed a further 1.5-fold increase of AMPKa phosphorylation
compared to control hepatocytes, while cells treated with the
known AMPK activator AICAR (5-aminoimidazole-4-carboxa-
mide-1-b-d-ribofuranoside) induced an 8-fold induction of
AMPKa phosphorylation.
Previous results showed the involvement of the PI3K survival
pathway in the protective effect of TUDCA against GCDCA-
induced apoptosis [43]. Thus, we investigated whether the PI3K
pathway could be involved in the anti-apoptotic effects of
metformin, using the specific PI3K inhibitor, LY294002. Metfor-
min reduced the GCDCA-induced caspase-3 like activity with
52% (Fig. 5C). The protective effect of metformin against
apoptosis was completely abolished when the PI3K pathway was
blocked (Fig. 5C, E). In addition, the protein levels of phosphor-
ylated Akt, the downstream target of PI3K, increased in time after
Figure 4. Metformin reduces apoptosis without increasing necrotic cell death. Cells were exposed to GCDCA (50 mmol/L) for 4–16 hrs.
Metformin (1 mmol/L) was added 10 minutes before addition of GCDCA. Cells stimulated with H2O2 (5 mmol/L, 6 hrs) were used as positive control.
Sytox green nuclear staining was used to determine necrotic cell death. N= 5. Representative images 4 hrs and 16 hrs after stimulation are shown,
percentages in panels indicate % of necrotic cells. Upper panel: phase contrast. Lower panel: fluorescence. Magnification 10X.
doi:10.1371/journal.pone.0071773.g004
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exposure to metformin (Fig. 5D). As described previously [43], a
significant increase in GCDCA-induced apoptosis was observed
when the PI3K pathway was inhibited in hepatocytes (Figure 5C).
Metformin is not an Inhibitor of NF-kB
Since inhibition of NF-kB sensitizes hepatocytes to TNFa-
induced cell death [37], it is important to determine the effect of
metformin on NF-kB activation, prior to its use in inflammatory
(TNFa-mediated) liver diseases. Therefore, we studied the
involvement of NF-kB signaling in the protective effects of
metformin. Previous studies demonstrated strong NF-kB-depen-
dent cytokine-induced expression of inducible nitric oxide synthase
(iNOS) in hepatocytes [37]. Cytokine mixture induces a 200-fold
induction of iNOS expression compared to control cells (Fig. 6A),
which was not affected by metformin. As expected, the transcrip-
tional inhibitor actinomycin D completely blocked cytokine-
induced iNOS expression (Fig. 6A). Metformin alone did not
induce iNOS expression and showed expression levels similar to
control hepatocytes (Figure 6A). The qPCR results were confirmed
using the caspase-3 assay. TNFa alone, or in combination with
1 mmol/L metformin did not induce caspase-3 activation (Fig. 6B).
In contrast, caspase-3 activity was strongly induced in hepatocytes
exposed to TNFa in combination with actinomycin D. Metformin
exposed hepatocytes showed caspase-3 levels similar to control
cells (data not shown).
Discussion
In this study we investigated the hepatoprotective effects of
metformin in models of TNFa- and bile acid-induced apoptosis in
primary rat hepatocytes. Other studies described that metformin
improves the viability of hepatocytes in fatty livers and reduced
serum levels of ALT and AST in NASH [6–8]. We show that
metformin is protective against bile acid-induced cell death, while
it has no effect on TNFa-induced apoptosis. Metformin reduces,
but does not delay, GCDCA-induced caspase activity and nuclear
Figure 5. The protective effect of metformin involves the PI3-kinase/Akt pathway, but not the AMPK/mTOR pathway. (A) Primary rat
hepatocytes were exposed to GCDCA (50 mmol/L) and metformin (1 mmol/L) for 4 hrs with or without 59-iodotubercidin (0.1 mmol/L), an inhibitor of
AMP-activated protein kinase, and the mTOR inhibitor rapamycin (0.5 mmol/L). Caspase-3 like activity is presented as fold induction compared to
control values; control values were set at one. Data are presented as mean of at least three independent experiments +/2S.E.M. Statistical analysis: *
p,0.05 compared to control. # p,0.05 compared to GCDCA-treated cells. (B) Western blot analysis for AMPK phosphorylation on cell lysates (45 ml).
Lane 1: control hepatocytes; lane 2: GCDCA treated cells (50 mmol/L, 1 hr); lane 3: GCDCA plus metformin (1 mmol/L); lane 4: metformin (1 mmol/L);
lane 5: positive control: hepatocytes exposed to the known AMPK activator AICAR (250 mmol/L, 1 hr). All lanes are obtained from the same
membrane with the same detection reagent and exposure time. Western blots were quantified and band intensities of phosphorylated AMPKa were
expressed as ratio of the intensity of b-actin protein levels. Data are presented as mean of at least three experiments +/2 S.E.M. Control values were
set at one. A representative Western blot is shown. (C) Caspase-3 activity of heptacoytes exposed to GCDCA (50 mmol/L) for 4 hrs and metformin
(1 mmol/) with or without LY294002 (50 mmol/L). Caspase-3 like activity is presented as fold induction compared to control values. Control values
were set at one. Data are presented as mean of at least three independent experiments +/2 S.E.M. (D) Western blot analysis for Akt phosphorylation
on cell lysates (45 ml). Left side. Lane 1: control hepatocytes; lane 2, 3: metformin (1 mmol/L) 5 minutes exposed cells; lane 4, 5: metformin 10 minutes
exposed cells; lane 6, 7: metformin 30 minutes exposed cells; lane 8, 9: metformin 60 minutes exposed cells. Western blots were quantified and band
intensities of phosphorylated Akt were expressed as ratio of the intensity of GAPDH protein levels (Right side). Data are presented as mean of at least
three independent experiments +/2 S.E.M. Control values were set at one. A representative Western blot is shown. (E) Cells were exposed to GCDCA
(50 mmol/L) for 4 hrs with or without metformin (1 mmol/L), 59-iodotubercidin (0.1 mmol/L), rapamycin (0.5 mmol/L), or LY294002 (50 mmol/L).
Nuclear condensation as indicated by acridine orange staining is shown, and expressed as % condensed nuclei. Magnification 20X. Representative
images are shown. N = 4 for each experiment (A–E).
doi:10.1371/journal.pone.0071773.g005
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condensation, but has no effect on TNFa/ActD-induced hepato-
cyte apoptosis. The opposite effects of metformin in these two
models of hepatocyte apoptosis is most likely due to the
involvement of different signaling pathways in cytokine and bile
acid induced apoptosis. Cytokines like TNFa exert their effects via
death receptors at the cell membrane, while bile acids need to be
taken up by the bile acid transporter, Ntcp [46–48]. Furthermore,
bile acid-induced apoptosis has been demonstrated to involve
activation of the Fas pathway via EGF-receptor phosphorylation
[49]. TNFa is known to activate the transcription factor NF-kB,
while we have previously shown that GCDCA has no effect on
NF-kB signaling [42].
To elucidate the protective mechanism of metformin, we first
excluded the possibility that metformin is hepatoprotective via
inhibition of GCDCA-uptake at the cell membrane. The results
obtained with the fluorescent bile acids clearly demonstrated that
metformin has no effect on bile acid uptake. Furthermore,
metformin was able to reduce apoptosis when added up to 2 hrs
after bile acid exposure. These data suggest that metformin does
not interfere with bile acid uptake and activates survival pathways
very rapidly. In this respect, the protective effect of metformin
resembles the protective effect of TUDCA, TUDCA was
protective against GCDCA-induced cell death when added up
to 2 hrs after the bile acid [43]. We confirm previous findings [43],
that 2 hours after GCDCA exposure, caspase-3 activation is still
Figure 6. Metformin does not inhibit NF-kB activation. qPCR analysis for iNOS using cDNA of primary rat hepatocytes exposed for 4 hrs to
cytokine mixture with or without 1 mmol/L metformin. The transcriptional inhibitor actinomycin D (200 ng/ml) served as positive control for NF-kB
inhibition. (A). Metformin does not reduce cytokine mixture induced iNOS mRNA expression. (B) Metformin does not sensitize hepatocytes to TNFa-
induced apoptosis. Caspase-3 like activity was measured in primary rat hepatocytes exposed to TNFa (20 ng/ml, 16 hrs) with or without metformin
(1 mmol/L) or actinomycin D (200 ng/ml, positive control for induction of TNFa-induced caspase-3 activity). Caspase-3 activity is shown as fold
induction compared to control values; control values were set at one. N= 5 for each experiment. Statistical analysis: Fig. 6A * p,0.05 or & p,0.01
compared to control. # p,0.01 compared to cytokine mixture-treated cells.# p,0.01 compared to cytokine mixture plus metformin-treated cells.
Fig. 6B * p,0.05 compared to control. # p,0.05 compared to TNFa-treated cells. # p,0.05 compared to TNFa plus metformin-treated cells.
doi:10.1371/journal.pone.0071773.g006
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minimal, and apoptosis can be prevented, while beyond this
threshold the apoptotic machinery cannot be reversed anymore.
Previously, we demonstrated that under particular conditions
the mode of cell death can shift from apoptosis to necrosis [44]. In
this study, metformin does not cause a switch from apoptotic to
necrotic cell death. The percentage of necrotic cells is similar for
GCDCA and GCDCA plus metformin treated hepatocytes.
Furthermore, metformin does not significantly reduce GCDCA-
induced necrosis. These results demonstrate that metformin only
protects against apoptotic cell death, but not against necrotic cell
death.
Since the AMPK/mTOR pathway is an important downstream
target of metformin, we investigated the involvement of these
pathways in the protective effect of metformin. Our results
demonstrate that the AMPK/mTOR signaling pathway is not
involved in the anti-apoptotic actions of metformin [16,17,26,50].
Both known inhibitors for AMPK and mTOR, 59-iodotubercidin
and rapamycin, had no effect on the reduction in GCDCA-
induced apoptosis caused by metformin. Although AMPK does
not appear to be involved in the protective effect, it is of interest to
note that GCDCA slightly increased the phosphorylation and
activation of AMPK. The mechanism of this effect and its
relevance remains to be elucidated. Since AMPK is not involved in
the protective actions of metformin, the drug must exert its anti-
apoptotic actions via other pathways. Our results demonstrate that
the PI3K/Akt pathway plays an important role in the protective
effect of metformin. The protective effect of metformin against
GCDCA-induced apoptosis is dependent on an intact PI3K
pathway. These data are in accordance with other reports
emphasizing the importance of PI3K/Akt in the protection
against bile acid-induced apoptosis [34–36,38,39,43]. On the
contrary, our data imply that members of the MAP kinase family
are not involved in the anti-apoptotic signaling of metformin, since
inhibitors of the anti-apoptotic MAP kinases ERK and p38 do not
reduce the protective effect of metformin (data not shown).
The possibility that GCDCA sensitizes hepatocytes to NF-kB
activation can be excluded, since metformin, either alone or in
combination with GCDCA, did not induce the expression of the
NF-kB-dependent gene iNOS. One study reported caspase-
regulated Bcl-xl expression, via caspases downstream of ERK1/
2. Using the specific ERK1/2 inhibitor U0126, Bcl-xl expression
was reduced and apoptosis was induced. This U0126-induced
down-regulation of Bcl-xl was reversed by the pancaspase inhibitor
Z-VAD-FMK [51]. Although a different cell type was used,
caspase-dependent Bcl-xl expression could explain our results: in
our model GCDCA-induced caspase activity is reduced by
metformin and this could subsequently result in an additional
increase in Bcl-xl expression.
Our results clearly demonstrate that metformin does not inhibit
NF-kB activity. Hepatocytes are not sensitized to TNFa-induced
apoptosis by metformin, and metformin does not affect cytokine
induced NF-kB-dependent gene transcription. Our data are
conflicting with some reports describing AMPK-mediated inhibi-
tion of NF-kB by metformin [52,53]. However, these studies are
not performed in hepatocytes but in endothelial cells, which could
explain the discrepancy. Furthermore, these reports show the
involvement of AMPK in metformin signaling, while in our study
AMPK is not involved in the anti-apoptotic actions of metformin.
In summary, we have shown that metformin is protecting
hepatocytes against GCDCA-induced apoptosis, while metformin
has no effect on TNFa/ActD-induced apoptosis. The PI3K/Akt
survival pathway is required for the anti-apoptotic effect of
metformin; however the protection is independent of the AMPK/
mTOR signaling pathway. In addition, we have demonstrated
that metformin does not inhibit NF-kB activity and hence does not
sensitize hepatocytes to TNFa-induced apoptosis. The latter
finding would make metformin suitable in the treatment of
chronic liver diseases, in which an inflammatory component is
present.
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